Elie Marcheteau
Overview
Explore the profile of Elie Marcheteau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
2085
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brouillard M, Mathieu T, Guillot S, Meducin F, Roy V, Marcheteau E, et al.
Int J Pharm
. 2024 Sep;
665:124683.
PMID: 39265850
Emerging and reemerging viruses pose significant public health threats, underscoring the urgent need for new antiviral drugs. Recently, a novel family of antiviral acyclic nucleoside phosphonates (ANP) composed of a...
2.
Frenois-Veyrat G, Gallardo F, Gorge O, Marcheteau E, Ferraris O, Baidaliuk A, et al.
Nat Microbiol
. 2022 Nov;
7(12):1951-1955.
PMID: 36344621
The ongoing monkeypox virus (MPXV) outbreak is the largest ever recorded outside of Africa. We isolated and sequenced a virus from the first clinical MPXV case diagnosed in France (May...
3.
Palle J, Hirsch L, Lapeyre-Prost A, Malka D, Bourhis M, Pernot S, et al.
Cancers (Basel)
. 2021 Nov;
13(21).
PMID: 34771724
Elucidating mechanisms involved in tumor-induced immunosuppression is of great interest since it could help to improve cancer immunotherapy efficacy. Here we show that Hepatocyte Growth Factor (HGF), a pro-tumoral and...
4.
Marcheteau E, Farge T, Peres M, Labrousse G, Tenet J, Delmas S, et al.
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439212
Triple-negative breast cancer (TNBC) is notoriously aggressive with a high metastatic potential, and targeted therapies are lacking. Using transcriptomic and histologic analysis of TNBC samples, we found that a high...
5.
Imbert C, Montfort A, Fraisse M, Marcheteau E, Gilhodes J, Martin E, et al.
Nat Commun
. 2020 Jan;
11(1):437.
PMID: 31974367
Immune checkpoint inhibitors (ICIs) have dramatically modified the prognosis of several advanced cancers, however many patients still do not respond to treatment. Optimal results might be obtained by targeting cancer...
6.
Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, et al.
Gastric Cancer
. 2019 Jul;
23(1):73-81.
PMID: 31267360
Background: The correlation between immune cells and the Lauren classification subtypes and their prognostic impact in advanced gastric cancer (AGC) are unknown. Methods: Circulating natural killer (NK) cells, CD4 and...
7.
Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, et al.
Nat Commun
. 2017 Dec;
8(1):2256.
PMID: 29273790
Antibodies against programmed cell death-1 (PD-1) have considerably changed the treatment for melanoma. However, many patients do not display therapeutic response or eventually relapse. Moreover, patients treated with anti-PD-1 develop...
8.
Nizard M, Roussel H, Diniz M, Karaki S, Tran T, Voron T, et al.
Nat Commun
. 2017 May;
8:15221.
PMID: 28537262
Tissue-resident memory T cells (Trm) represent a new subset of long-lived memory T cells that remain in tissue and do not recirculate. Although they are considered as early immune effectors...
9.
Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, et al.
Eur J Cancer
. 2017 Apr;
79:15-22.
PMID: 28456090
Background: The identification of dynamic biomarkers in advanced gastric and oesogastric junction adenocarcinoma (GOA) could help to tailor strategies for each patient. Enumeration of circulating tumour cells (CTCs) is approved...
10.
Desbois M, Vu P, Coutzac C, Marcheteau E, Beal C, Terme M, et al.
J Immunol
. 2016 May;
197(1):168-78.
PMID: 27217584
Tumors with the help of the surrounding environment facilitate the immune suppression in patients, and immunotherapy can counteract this inhibition. Among immunotherapeutic strategies, the immunostimulatory cytokine IL-15 could represent a...